Breast Cancer Clinical Trials in Grand Rapids, Michigan

10 studies are recruiting for breast cancer in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

   The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The Cancer & Hematology Centers, Grand Rapids, Michigan

   Locations

   567 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06492616 on ClinicalTrials.gov

2. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

   This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan

   Locations

   241 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06790693 on ClinicalTrials.gov

3. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

4. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

   This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan

   Locations

   210 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT05646862 on ClinicalTrials.gov

5. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

   This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inop…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Grand Rapids, Michigan

   Locations

   320 in total

   Run by

   AstraZeneca

   See if you can join NCT06103864 on ClinicalTrials.gov

6. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

7. E-Mindfulness Approaches for Living After Breast Cancer

   NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

   Stage

   Phase 3

   Ages

   18 to 50

   Site

   Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan

   Locations

   383 in total

   Run by

   NRG Oncology

   See if you can join NCT06748222 on ClinicalTrials.gov

8. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

   Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherap…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   65 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT05768139 on ClinicalTrials.gov

9. Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

   This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START, Midwest, Grand Rapids, Michigan

   Locations

   7 in total

   Run by

   MBrace Therapeutics

   See if you can join NCT07145255 on ClinicalTrials.gov

10. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    6 in total

    Run by

    Tanabe Pharma America, Inc.

    See if you can join NCT06943521 on ClinicalTrials.gov